Submit your research today!
Your valuable research in Expert Opinion on Drug Discovery - The discovery and development of RNA-based therapeutics
About the special issue
The field of psychiatry therapeutics has pivoted in the last 2-3 years towards so called ""rapid acting antidepressants"" (RAADs). The first FDA approved RAAD is esketamine and just recently, our Editor-in-Chief Professor Roger S. McIntyre has led the international guidelines for esketamine and ketamine.
In addition, there are a disparate assortment of ""psychedelics"" that are being developed. Although we certainly welcome potentially innovative and lifesaving treatments for persons with mental disorders, we also need to have a measured and empirically guided understanding of safety.
This special focus issue therefore aims to provide a broad-ranging overview of the safety of these exciting new treatments for persons with mental disorders. We welcome contributions in the form of reviews, perspectives, editorials, specific drug evaluations and original research.
By publishing in Expert Opinion on Drug Safety you will:
- Gain recognition from an international audience and increase your opportunities for future collaboration
- Receive 50 free e-prints & promotional tips on promoting your article courtesy of our Author Services site
- Immediately see the impact of your research made in the community by tracking downloads, citations, and the Altmetric Score of your article on My Authored Works
- Increase the discoverability of your research with MEDLINE listings and more